HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- GVHD management improves, but questions remain about risk stratification, prophylaxis
-
- Should research efforts focus on completely preventing GVHD?
- Delivering on the promise of precision oncology John Sweetenham, MD, FRCP, FACP
- Abemaciclib effective as initial therapy for certain women with advanced breast cancer
- Alectinib improves lung cancer symptoms longer than crizotinib
- Atezolizumab plus chemotherapy improves PFS in non-small cell lung cancer
- Atezolizumab provides long-term lung cancer survival benefit
- Breast cancer screening linked to lower stage at diagnosis, less intensive treatment
- Calcium channel blockers may increase risk for pancreatic cancer
-
- Coordinating nurses improve quality of life, satisfaction with lung cancer care
- Directly proceeding to HSCT after remission improves ALL outcomes
- Monitoring tool lowers symptom severity for head, neck cancer
- Neoadjuvant pembrolizumab appears effective for resectable melanoma
- Only 1.9% of eligible heavy smokers screened for lung cancer
- Pembrolizumab plus CMP-001 demonstrates efficacy for anti-PD-1 resistant melanoma
- Researcher: Criteria for breast cancer genetic testing ‘should be abolished’
- Upstaging of lung cancer increases with surgery delay
-
- World Trade Center responders may face increased cancer burden, elevated myeloma risk
- Gene therapy reduces need for transfusions in beta-thalassemia
- Genetic counseling underused for breast cancer
- Immune checkpoint inhibitors reach most patients within 4 months after FDA approval
- FOLFOXIRI plus cetuximab active, feasible for metastatic colorectal cancer
- Radiographic PFS feasible endpoint for metastatic castration-resistant prostate cancer trials
- Hypomethylating agents alone show poor long-term OS for high-risk myelodysplastic syndrome
- Selinexor plus dexamethasone active in refractory multiple myeloma
-
- Young adults, adolescents with acute lymphoblastic leukemia fare better with pediatric care
- FDA expands approval of Kymriah to include relapsed or refractory large B-cell lymphoma
- FDA grants orphan drug designation to LBS-007 for acute lymphoblastic leukemia
- FDA grants priority review to Keytruda as part of non-small cell lung cancer regimen
- FDA grants fast track designation to EC-18 for chemoradiation-induced oral mucositis
- FDA approves Tafinlar-Mekinist combination for adjuvant treatment of BRAF-mutant melanoma
- Longer donor leukocyte telomere reduces infection-related mortality in aplastic anemia
- Durvalumab-tremelimumab combination fails to prolong survival in PD-L1-low non-small cell lung cancer
-
- Tecentriq, Cotellic combination fails to improve survival in heavily pretreated colon cancer